Bone Biologics (BBLGW) Non-Current Debt (2014 - 2019)

Bone Biologics (BBLGW) has reported Non-Current Debt for 6 consecutive years, with $11.3 million the latest figure, recorded in Q4 2019.

• On a quarterly basis, Non-Current Debt changed N/A year-over-year to $11.3 million in Q4 2019; TTM through Dec 2019 was $11.3 million, a N/A change from a year earlier, with the FY2019 full-year figure at $11.3 million, changed N/A from the prior year.
• Non-Current Debt was $11.3 million for Q4 2019 at Bone Biologics, up from $9.0 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $11.3 million in Q4 2019 and troughed at $3.8 million in Q1 2015.
• A 5-year average of $6.9 million and a median of $6.7 million in 2017 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 1578.72% in 2015 and increased 7.16% in 2016, its largest moves.
• Over 5 years, Non-Current Debt stood at $5.1 million in 2015, then surged by 48.8% to $7.6 million in 2016, then increased by 8.81% to $8.2 million in 2017, then gained by 9.36% to $9.0 million in 2018, then climbed by 25.78% to $11.3 million in 2019.
• The last three Non-Current Debt figures came in at $11.3 million (Q4 2019), $9.0 million (Q3 2018), and $8.6 million (Q2 2018), per Business Quant data.